@article { author = {}, title = {Determination of HER-2/neu by Chromogenic in Situ Hybridization on Borderline (2+) Immunohistochemistry Cases in Carcinoma Breast}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {12}, number = {1}, pages = {211-214}, year = {2011}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Objective: To determine the HER-2/neu status by chromogenic in situ hybridization (CISH) on tissue specimenswith a borderline (2+) immunohistochemistry (IHC) score in carcinoma breast by a descriptive, cross-sectionalstudy in the Histopathology Department, Armed Forces Institute of Pathology (AFIP), Rawalpindi from Jun 2008to Dec 2009. Methods: Tissue block specimens from 50 consecutive patients having HER-2/neu score of borderline(2+) on IHC assay were tested for HER-2/neu gene amplification by CISH. Mean and standard deviation werecalculated for quantitative variables like age and HER-2/neu gene copy signal/clusters by using SPSS version14. Frequencies and percentages were also calculated for qualitative variables like type of carcinoma and resultsof HER-2/neu by CISH (amplified/nonamplified). Results: HER-2/neu gene amplification by CISH was foundin 10 (20%) out of 50 patients with borderline (2+) IHC score. All CISH amplified cases belonged to invasiveductal carcinoma type. No significant correlation was noted between type of carcinoma and HER-2/neu geneamplification. Conclusion: Chromogenic in situ hybridization (CISH) is a practical, cost-effective and reliablemethod for analysis of HER-2/neu borderline (2+) cases which may be candidates for Herceptin therapy.}, keywords = {Breast carcinoma,chromogenic in situ hybridization,HER-2/neu,immunohistochemistry}, url = {https://journal.waocp.org/article_25498.html}, eprint = {https://journal.waocp.org/article_25498_bff7a316a52ac6a0977e8c2dd1f0a4ef.pdf} }